Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The mechanistic target of rapamycin complex 1 (mTORC1) FKBP12-rapamycin binding (FRB) domain is a highly conserved structural motif within the mTOR protein, specifically spanning residues 2021 to 2114 in humans (UniProt: P42345). This domain is the primary site for the inhibitory action of the natural product rapamycin and its synthetic analogs, which act by forming a ternary complex with the intracellular protein FKBP12 and the FRB domain (PubMed: 15268862). mTORC1 functions as a master regulator of cellular metabolism, integrating environmental cues such as nutrient availability and growth factor signaling to promote protein synthesis and inhibit autophagy (PubMed: 28077483). In many human pathologies, including various cancers and the genetic disorder tuberous sclerosis, the mTORC1 pathway is constitutively overactive, leading to uncontrolled cell proliferation (PubMed: 22541431). By targeting the FRB domain, rapalogs effectively dampen this signaling, making the domain a cornerstone of modern immunosuppressive and oncology therapies. Furthermore, the FRB domain's unique ability to undergo ligand-induced dimerization has made it a vital tool in synthetic biology for controlling protein-protein interactions (PubMed: 8816753). Structurally, the FRB domain consists of a four-helix bundle that provides a hydrophobic pocket for the rapamycin molecule to dock (PubMed: 8816753). Unlike ATP-competitive inhibitors, drugs targeting the FRB domain are allosteric inhibitors that specifically affect mTORC1 while having less immediate impact on mTORC2 (PubMed: 15268862).
Rapamycin and its analogs (rapalogs) form a gain-of-function complex with the immunophilin FKBP12; this binary complex then binds to the FRB domain of mTORC1, sterically inhibiting its kinase activity toward specific substrates like p70S6K (PubMed: 15268862).
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mechanistic target of rapamycin complex 1 FKBP12-rapamycin binding domain (mTORC1 FRB domain).